Tag: diabetes

AZ’s Diabetes Drug Reduces Heart Failure Risk

Farxiga reduced hospitalisation for heart failure regardless of ejection fraction status. Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxi...

Pfizer to License AnTolRx Type 1 Diabetes Therapy

AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. has exercised the option granted under a June 2016 agreement to license an immune tole...

Lilly Launches Low-Priced Insulin

Authorized generic version of Humalog will be available in U.S. pharmacies at 50 percent lower list price. Reinforcing the commitment to lower out-of-pocket costs for people who need insulin, Eli L...

Novo Nordisk Submitted Label Updates for its Insulin Aspart

Novo Nordisk announced that it has submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (fast-acting insulin aspart), seeking approva...

EMA Comittee Backs Sanofi and Lexicon Diabetes Med

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Marketing Authorization of Zynquista™ (sotagliflozin), developed by Sanofi a...

First Human Study of Pill Designed to Replace Injections

Safety and tolerability of RaniPill™ Capsule in humans advances oral delivery of injectable biologic drugs. The first human study of a pill designed to replace injections of biologics is today bein...

Boehringer and Lilly’s 2 Diabetes Drug Met Endpoint

Boehringer Ingelheim and Eli Lilly and Company announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined a...

EMA Recommended AstraZeneca’s Type I Diabetes Drug

AstraZeneca’s Forxiga (dapagliflozin) has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin i...

Novo Nordisk Expects Fast-Track Review for New Semaglutide

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US. The FDA grants ...

FDA Votes Divided on Sanofi’s Diabetes Drug

The future of Sanofi and Lexicon’s oral diabetes drug Zynquista hangs in the balance after an FDA advisory committee was split on whether the drug would benefit patients. The Endocrinologic and Met...

Japanese Company to Develop Type 1 Diabetes Cell Therapy

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with To...

Novartis and Gan & Lee to Produce Insulin Biosimilars

Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China’s Gan & Lee on versions of three blockbuster brands as the U.S...

Novo Nordisk signed a Deal with e-Therapeutics to find Therapies for diabetes

e-Therapeutics will work with Novo for a year and use its technology to identify novel intervention strategies, biological pathways and compounds that could form the basis of new therapies. The UK ...